Abstract
In REFLEX, subcutaneous interferon β-1a (scIFNβ-1a) reduced conversion to McDonald (2005 criteria) and clinically definite (CD) multiple sclerosis (MS) versus placebo in patients with a first clinical demyelinating event. Retrospective analysis demonstrated overall results were unchanged after application of McDonald-2010 MS criteria. Revised McDonald-2017 MS criteria included presence of cerebrospinal fluid specific oligoclonal bands, symptomatic lesions, and cortical lesions. Effect of scIFNβ-1a on time to McDonald-2005 MS and CDMS, and annualised relapse rate (ARR) during REFLEX was assessed, stratified by retrospective diagnosis of patients at baseline that did/did not meet McDonald-2017 MS criteria.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
